Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.

NCT02091245 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02091245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02091245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 31, 2014
Completion date
December 31, 2026
Enrollment
16 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia (cml) in blast crisis, refractory acute lymphoblastic leukemia (all), refractory acute myelogenous leukemia (aml), refractory biphenotypic leukemia, refractory mixed lineage leukemia, relapsed acute lymphoblastic leukemia (all), relapsed acute myelogenous leukemia (aml), relapsed biphenotypic leukemia, relapsed mixed lineage leukemia